





ORDs Computational Toxicology Research Program Briefing for Region 6


January 10, 2006


Robert Kavlock National Center for Computational Toxicology US Environmental Protection Agency Research Triangle Park, NC

Enabling ("Omic") Technologies










RESEARCH & DEVELOPMENT

RESEARCH & DEVELOPMENT Building a Source/Stressor Formation scientific Effect/Outcome foundation for sound Environmental environmental **Biological Event** Concentration decisions Exposure Dose


PROGRAMMATIC CHALLENGES

- Many Priority Lists Already in Queue (e.g., EDC's, Pesticide Inerts, HPV's, CCL) with No Risk-Based Criteria for Setting Testing Priorities
- Different Authorities Different Testing Requirements with No Scientific Basis for Flexible Testing Approaches
- Lack Data Needed to Reduce Uncertainties by Quantitative Risk Assessments (e.g., extrapolations)





Program Development



RESEARCH & DEVELOPMENT


ORD's Computational Toxicology Research Program

Themes:

- A technology-based, hypothesis-driven effort to increase the soundness of risk assessment decisions within EPA
- Build the capacity to prioritize, screen and evaluate chemicals by enhancing the predictive understanding of toxicity pathways


Success:

Measured by ability to produce faster and more accurate risk assessments for less cost relative to traditional means and to classify chemicals by their potential to influence molecular and biochemical pathways of concern



www.epa.gov/comptox

RESEARCH & DEVELOPMENT



RESEARCH & DEVELOPMENT

National Exposure Research Laboratory

Human and ecosystem exposure to pollutants

National Center for Environmental Research

Extramural grants in all research areas

National Health and Environmental Effects Research Lab Effects of contaminants on human health and ecosystems

National Center for Computational Toxicology Merging of computational and molecular approaches

National Center for Environmental Assessment Human health and ecological risk assessment

National Homeland Security Research Center

Responses to attacks against buildings and water treatment systems

National Risk Management Research Lab


Preventing and reducing risks to humans and the environment




- To provide **scientific expertise and leadership** related to the application of mathematical and computational tools and models
- To improve the predictive capabilities of the methods, models and measurements that constitute the input materials to the computational models.
- To **conduct and/or sponsor research** to provide models for fate and transport of chemicals, environmental exposures to humans and wildlife, delivery of the chemical to the target site of toxicity, molecular and cellular pathways of toxicity, and ultimately systems level understanding of biological processes and their perturbation
- Maintain a strong emphasis on the development of partnerships with other government and private organizations

RESEARCH & DEVELOPMENT


Program Development: Formation and Staffing of a National Center for Computational Toxicology





RESEARCH & DEVELOPMENT

The NCCT is part of a larger whole...



RESEARCH & DEVELOPMENT

Computational Toxicology Implementation and Steering Committee

(Jan 04 – present)

- NCEA
 - Ines Pagan
 - Paul White
- NCER
 - Susan Laessig
 - David Mustra
- NERL
 - Tim Collette
 - Greg Toth
- NHEERL
 - Gerald Ankley
 - Jack Fowle
 - Doug Wolf
- NHSRC
 - Chandrika Moudgal
- NPD
 - Elaine Francis
- NRMRL
 - Jorge Santo Domingo
 - Doug Young
- **RESEARCH & DEVELOPMENT**

- OPPTS
 - Vickie Dellarco
 - Yin-Tak Woo
- OAR
 - Scott Jenkins
- OW
 - Steve Kueberuwa
 - Clifton Townsend
- Regions
 - David Macarus (Reg 5)

Program Development: Implementing a Cross-ORD Research Portfolio

Amphibian Systems Model


Fish Proteomics Fish Toxicogenomics Fish metabonomics

Conazole MOA

Children's Health Pulmonary Biomarkers

Microbial Metagenomics

STAR Systems Models



DSSTox

Metabolic Simulator

ASTER


ER Binding Data Molecular Docking ER/AR Scale up H295R Assay Iconix Contract

STAR HTPS RFA

QRA

Diesel Particles HPG Axis Model Pellston, SOT and NCEA Workshops

RESEARCH & DEVELOPMENT



Proof of Concept Studies

- ER Binding data refinement
- ER QSAR Enhancement
- Steroid docking model studies
- H295R Assay evaluation
 - In vitro assay for steroidogenesis using a human cell line
- ER and AR Transcription Assay scale up
 - To use NHEERL developed cell lines, or equivalent
- Predictive Toxicogenomics evaluation
 - Hepatic gene changes following acute exposure in rat
 - Groups of chemicals from 2 classes of hepatotoxicants

RESEARCH & DEVELOPMENT

H295R Development

TABLE A Fold Differences in Cone Expression for U20ED Calls Expressed to Model Chemicale®

TABLE 4. Fold Differences	in Gene	Expres	SION TOP H	295K Ce	IIS EXPOS	ed to Mo	del chemic	alsª				
Chemical	CYP17	StAR	CYP11A	CYP19	CYP21	HMGR	17β HSD1	3β HSD1	3β HSD2	CYP11B2	CYP11B1	
8-Br-cAMP PMA forskolin lovastatin	₩↓ † †	† † †	t	†† †† ††	Inducer: 111 111 111 111	s †	Ļ	† † ††	*** ***	*** *** ***	111 11 111 1	
					Inhibitor	s						
spironolactone				t							t	
DL-aminoglutethimide					Ļ		t	t	Ļ		ttt A	
daidzein		÷.			1		tΛ	tΛ	tΛ	tΛ	ttt A	
ketoconazole			†Λ		tΛ		tΛ	tΛ		t	1	
spironolactone				Ť							T .	
DL-aminoglutethimide							т • •	T .	· · ·		ttt Λ	
daidzein kotoconozolo		*	* *		* A		†Λ	†Λ * ^	$\uparrow \Lambda$	†Λ.	ttt Λ	
ketoconazole			ŤΛ		ΓA		tΛ	tΛ		1	1	

* Symbols indicate fold difference relative to control; 1=2-fold or more; 1=5-fold or more; 1=10-fold or more. Λ = response recovered at highest concentration. All other differences are less than 2-fold.

Zhang, X., R. Yu, P. D. Jones, J. L. Newsted, T. Gracia, M. Hecker, K. Hilscherova, J. T. Sanderson, R. Wu, and J. P. Giesy. 2005. Quantitative RT-PCR Methods for Evaluating Toxicant-Induced Effects on Steroidogenesis Using the H295R Cell Line. *Environ. Sci. Technol.* 39:2777-2785.

RESEARCH & DEVELOPMENT

STAR Environmental Bioinformatics Centers

- RFA The successful applicant will:
 - Provide a multidisciplinary approach to development and application of computational methods that target multiple points along source-to-outcome continuum;
 - Presents opportunities for investigators with differing expertise to work together on larger issues than could be addressed in a single grant or cooperative agreement proposal;
 - Discuss application and development of bioinformatics standards and nomenclature, which will increase the portability and usability of Center-developed resources and tools.
 - Funding via a Cooperative Agreement
 - Five year duration
- Recipients (October 2006)
 - UMDNJ and UNC
- David Mustra, NCEA, Project Officer

RESEARCH & DEVELOPMENT

Partnerships

- Internal EPA
 - Communities of Practice
 - Chemoinformatics, Prioritization, Biological Modeling
- Federal
 - Department of Energy
 - Department of Defense
 - FDA/NCTR
 - NIEHS/NTP
 - NIH/MLI
- Private Sector
 - IBM
 - Affymetrix
 - CIIT Centers for Health Research
 - SBIR Solicitations
- International
 - ITSC (Former Soviet Union weapons scientists)

RESEARCH & DEVELOPMENT

EPA Data Challenges:

- "Electronification" of historical data
- Structure-annotation
- Data standardization & integration



InChI text annotation
EPA Structure-browser
Collaborations with ATSDR, ECB, FDA, NIEHS

U.S. Environmental Protection Agency



About DSSTox

Work in Progress

Frequent Questions

Databases

Central Field Definition Table

Apps, Tools & More

DSSTox Community

Site Map

Glossary of Terms

Help

Distributed Structure-Searchable Toxicity (DSSTox) Public Database Network

Recent Additions | Contact Us | Print Version Search:

http://www.epa.gov/nheerl/dsstox

EPA Home > Research & Development > Health and Environmental Effects Research > Distributed Structure-Searchable Toxicity (DSSTox) Public Database Network

DSSTox

The Distributed Structure-Searchable Toxicity (DSSTox) Database Network is a project of <u>EPA's Computational Toxicology Program</u>, helping to build a public data foundation for improved structure-activity and predictive toxicology capabilities. The DSSTox website provides a public forum for publishing downloadable, standardized toxicity data files that include chemical structures. More

Recent Additions: 1Mar05

***New Database Additions:

 FDA Maximum (Recommended) Daily Dose Database (FDAMDD) of 1217 pharmaceuticals - 1Mar05

***Expanded and modified versions:

 Consolidated, updated Carcinogenic Potency Database - All Species (CPDBAS), 1451 compounds: 91 new records added to v2a


CAS registry numbers added to EPAFHM and DBPCAN

***New Standard Fields added to all DSSTox files:

- INChI (IUPAC/NIST Chemical Identifier) unique structure-text codes
- <u>IUPAC</u> systematic chemical names (generated by ACD/Name)
- <u>Standard Toxicity Fields</u>: StudyType, Species, Endpoint fields

***New Features of Site:

- <u>FTP Download Instructions</u> for easy access to archived and new DSSTox data files
- New information pages: INChI, DSSTox Standard Toxicity Fields
- Links to External Public Databases adopting DSSTox standards: ISSCAN new




DSSTox Graphic Flowchart

- DSSTox Project Goals
- DSSTox Publications

DSSTox Databases:
CPDBAS_v2a_1451_1Mar05
DBPCAN v2a 209 1Mar05
EPAFHM v2a 617 1Mar05
FDAMDD v1a 1217 1Mar05**
NCTRER v2a 232 1Mar05


** new addition

DSSTox Chemoinformatics Total Records: 6625 Total Unique Records: 3967 (no replicates)




Molecular Docking

Crystal structure from the literature




1E3G Human Androgen Receptor Ligand Binding Domain with Ligand Metribolone (R1881) Computationally created target



1E3G Human Androgen Receptor Ligand Binding Domain with Ligand removed computationally


RESEARCH & DEVELOPMENT

Dendrogram of Steroid Receptor Ligands against multiple Nuclear Receptors



Rabinowitz et al, Unpublished

Induction of Cytochrome P450s by EPA-A/B/C Similar to PXR/CAR Agonists, EPA-D/E Similar to PPAR- α Agonists



RESEARCH & DEVELOPMENT



ToxCast– A Prioritization Concept

QRA

- Assumptions
 - Prioritization/Categorization is needed
 - Prioritization is not equivalent to screening
 - Need broad coverage of potential outcomes
 - Outcomes mediated by chemical-biological interactions
 - There is no current model
 - Technological advances can be employed (e.g., HTS)
 - Cost is a factor in acceptance
- Pharmaceutical experience is helpful, but caveats
 - Focused on targets
 - Accepts a high false negative rate
 - "Activity" levels higher than for environmental chemicals
- Build upon examples where mode/mechanism of action has already, or is being, employed in hazard or risk assessment

RESEARCH & DEVELOPMENT

Enabling HTS Technologies Developed in the Search for Bioactive Compounds

- 96 to 384 to 1536 robotics revolution
- Compound/chemical libraries >10⁶
- Assay development and miniaturization
- Computational tools for management and analysis of large volumes of data

RESEARCH & DEVELOPMENT

Biological spectra analysis: Linking biological activity profiles to molecular structure PNAS January 11, 2005 vol. 102 no. 2 261–266

Anton F. Fliri*, William T. Loging, Peter F. Thadeio, and Robert A. Volkmann** CHEMISTRY PHARMACOLOGY

Pfizer Global Research and Development, Groton, CT 06340


Communicated by Larry E. Overman, University of California, Irvine, CA, October 25, 2004 (received for review September 4, 2004)

Establishing guantitative relationships between molecular structure and broad biological effects has been a longstanding challenge in science. Currently, no method exists for forecasting broad biological activity profiles of medicinal agents even within narrow boundaries of structurally similar molecules. Starting from the premise that biological activity results from the capacity of small organic molecules to modulate the activity of the proteome, we set out to investigate whether descriptor sets could be developed for measuring and quantifying this molecular property. Using a 1,567compound database, we show that percent inhibition values. A determined at single high drug concentration in a battery of in v/tro assays representing a cross section of the proteome, provide precise molecular property descriptors that identify the structure of molecules. When broad biological activity of molecules is represented in spectra form, organic molecules can be sorted by quantifying differences between biological spectra. Unlike traditional structure-activity relationship methods, sorting of molecules by using biospectra comparisons does not require know ledge p of a molecule's putative drug targets. To illustrate this finding, we selected as starting point the biological activity spectra of clotrimazole and tioconazole because their putative target, lanosterol demethylase (CYP51), was not included in the bloassay array. Spectra similarity obtained through profile similarity measurements and hierarchical dustering provided an unbiased means for establishing quantitative relationships between chemical structures and biological activity spectra. This methodology, which we have termed biological spectra analysis, provides the capability not only of sorting molecules on the basis of biospectra similarity but also of predicting simultaneous interactions of new molecules with multiple proteins.

biospectra | proteome | structure-function relationships

differences in biological environments (8). Considering the complexity of this requirement, computational solutions that precisely link molecular structure to broad biological response are currently not possible (9, 10). We report here an approach to structure-function studies that is based on measurements of the capacity of molecules to interact with the proteome (11).


Translation of Chemical Property Information into Biological Activity Spectra



Building a scientific foundation for sound environmental decisions

RESEARCH & DEVELOPMENT

ToxCast Information Domains




Potential Outcomes


- Ability to categorize or prioritize chemicals
 - Tool box of indicators across information domains
 - Cost effective approach for assessing potential to be biologically active agents
 - Potential targeting of outcomes of concern
- Flexibility
 - Adaptable to technological advances
 - Refinement of key indicators with experience
- Development of predictive models as database enlarges
- More effective and efficient use of animals in testing

RESEARCH & DEVELOPMENT


🥹 genome.gov 2005 Release NIH Nationwide Network of Molecular Libraries Screening Centers - Mozilla Firefox	
Eile Edit View Go Bookmarks Iools Help 🎇 🥪 룢 🕼	
🔄 🔹 🄄 👻 🚱 🏟 🚳 🔀 🗮 http://www.genome.gov/15014443	💌 🕟 Go 🔣
Best of the Web Channel Guide DSM Regional Affilia Windows Media Windows	
genome.gov National Human Genome Research Institute National Institutes of Health Home About NHGRI Newsroom Staff	
Research Grants Health Policy Educational Careers & Training	
Home > Newsroom > Current News Releases > 2005 Release NIH Nationwide Network of Molecular Libraries Screening Centers	Drint Version On Other Sites National Institutes of Health
National Institutes of Health	<u>National Institute of Mental</u> <u>Health</u>
NIH Creates Nationwide Network of Molecular Libraries Screening Centers To Accelerate Study of Human Biology and Disease	
"Roadmap" Grants Will Establish Nine New Centers in Seven States	-
BETHESDA, Md., Wed., June 15th, 2005 - The National Institutes of Health (NIH) today announced it is awarding \$88.9 million in grants to nine institutions over three years to establish a collaborative research network that will use high-tech screening methods to identify small molecules that c be used as research tools. Small molecules have great potential to help scientists in their efforts to learn more about key biological processes involved human health and disease.	
"This tremendous collaborative effort will accelerate our understanding of biology and disease mechanisms," said Elias A. Zerhouni, M.D., NIH director. "More importantly, it will, for the first time, enable academic researchers to explore novel ideas and enable progress on a broad front against human disease."	
For example, the broad-based screening effort will eventually enable researchers to explore the hundreds of thousands of proteins believed to be enco by the approximately 25,000 genes in the human genome. To date, only a few hundred human proteins have been studied in detail using small molecul probes.	
Certain small organic chemical compounds, also referred to as small molecules, can be valuable tools for understanding the many important cellular eve involved in health and disease, which is key to identifying possible new targets for diagnosis, treatment and prevention. To date, most useful small molecules have been found serendipitously. The molecular libraries screening program is an effort by NIH to take an efficient, high-throughput approac toward the discovery of many more useful compounds.	
The Molecular Libraries Screening Centers Network (MLSCN) is being developed through the NIH Roadmap for Medical Research. Specifically, the netwo part of the Roadmap's "New Pathways to Discovery" initiative, which has set out to advance the understanding of biological systems and build a bette "toolbox" for medical researchers in the 21st century. The network is funded by all of the institutes of the NIH and co-administered by the National Institute of Mental Health (NIMH) and the National Human Genome Research Institute (NHGRI) on behalf of NIH. The operation of the network will be overseen by a project team made up of staff from NIH's 27 institutes and centers.	
Data generated from the high-throughput assays conducted at the screening centers will be made available to researchers in both the public and priv sectors through the PubChem database at (<u>PubChem</u>), created and managed by the National Library of Medicine at NIH. The network's first screening center, the NIH Chemical Genomics Center (NCGC), was established in June 2004 by the NHGRI's intramural program to jumpstart the roadmap effort. Another critical component of the network is the Molecular Libraries Small Molecule Repository, located in San Francisco at Discovery Partners International, a drug discovery research firm. The repository houses the collection of small molecules that will be used for screening by the centers.	
Done	Auto Cop ENABLED
🛃 Start 🖉 🤨 👘 » 📵 Robert Kavlock - Inbo 🦉 EPA: EIMS Search Re 😻 genome.gov 2005 R 🔯 Microsoft PowerPoint	E" 📶 🕮 🗎 👬 🔐 🗞 🍊 🔁 🌽 📮 5:53 PM



Systems Biology Modeling



PK/PD Model of N- methyl Carbamate Activity




Example Response Metrics


Maximum inhibition: 5.8%

Fraction of time > 10%: 0%

Fraction of time > 5%: 7.6%

Fraction of time > 1%: 54%





NCCT - Near Term Objectives

- Development and implementation of advanced biological models
 - Statistical methods for parameter estimation
 - Probabilistic modeling framework
- Information technology development and application
 - Expansion of DSSTox, with sub-structure searching
- Prioritization method development and application
 - Flexible docking models for nuclear receptors
 - ToxCast proof of concept demonstration
- Advanced computational approaches for cumulative risk assessment
 - Visual analytical approach to exposure-body burden relationships

RESEARCH & DEVELOPMENT

